This study aims to evaluate the safety and effectiveness of the VentriCure interventional left ventricular assist system for short-term ventricular support during high-risk percutaneous coronary intervention (HRPCI) in non-emergent, hemodynamically stable coronary artery disease patients via a prospective, multi-center, randomized controlled clinical trial.

Inclusion Criteria:

1. Patient age ≥18 years old;
2. As assessed by the cardiac team the patient needs coronary revascularization, but CABG (Coronary Artery Bypass Grafting) is of high risk, or the patient refuses to undergo CABG;
3. The patient is meeting one of the following:

(1) Coronary Artery Disease and left ventricular ejection fraction ≤35%; (2) Coronary Artery Disease and left ventricular ejection fraction ≤40% and severe heart failure; 4. PCI was required for imaging diagnosis; 5. Patient willing and able to comply with protocol requirements and accept clinical follow-up; able to understand study purpose and sign informed consent.

Exclusion Criteria:

1. Cardiac arrest within 24 hours;
2. The implantation of an interventional left ventricular assist system was either contraindicated or not feasible;
3. ST-segment elevation myocardial infarction (STEMI) within 24 hours;
4. Chronic Kidney Disease;
5. Severe right heart failure or severe tricuspid regurgitation;
6. Presence of abnormal coagulation parameters (platelet count ≤75,000/mm^3, INR≥2.0, or fibrinogen ≤1.50g/L);
7. Moderate or higher anemia;
8. History of stroke or transient ischemic attack (TIA) within one month;
9. Allergy or intolerance to anticoagulants or contrast agent;
10. Active internal bleeding within a month;
11. Presence of uncontrolled active infection;
12. Pregnant or lactating women;
13. Patients are participating in other clinical trials;
14. Other circumstances that are determined by the investigator to be unsuitable for the study.